Family Forum / Parenting / Children's Health / August 2006

How about two:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8
896541&dopt=Citation

     J Infect Dis. 1996 Nov;174 Suppl 3:S330-4.

Efficacy of high-titer live attenuated varicella vaccine in healthy young
children.

Varis T, Vesikari T.

Department of Virology, University of Tampere Medical School, Finland.

The efficacy of a high-titer, reformulated varicella vaccine was studied in
513 10- to 30-month-old children. Vaccinees were randomly allocated to 5
groups to receive one of two lots of an original high-titer vaccine, one of
two lots of a partially heat-inactivated vaccine, or placebo. Both vaccines
were well tolerated. Seroconversion was detected in 100% and 99% of children
immunized with the high- and low-titer vaccines, respectively. Sixty-five
cases of serologically confirmed varicella-like disease were discovered
during follow-up (mean, 29.3 months): 5 in the high-titer vaccine group, 19
in the low-titer vaccine group, and 41 in the placebo group (P < or = .005
for each difference). Thus, the protective efficacy

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1
659052&dopt=Citation

     Vaccine. 1991 Sep;9(9):643-7.

Oka/Merck varicella vaccine in healthy children: final report of a 2-year
efficacy study and 7-year follow-up studies.

Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, Provost PJ,
Watson BA, Starr SE, Plotkin SA.

Department of Clinical Research, Merck Sharp & Dohme Research Laboratories,
West Point, PA 19486.

A large double-blind, randomized, placebo-controlled trial of live
attenuated Oka/Merck varicella vaccine was conducted among healthy children,
1-14 years of age. During the first varicella season, the efficacy of the
vaccine among susceptible children was 100%1. During the second varicella
season, 22 children were diagnosed with varicella; 21 cases in placebo
recipients and one in a vaccine recipient. The overall efficacy of the
vaccine through two varicella seasons was 98%. After the code for the study
was broken, the original group of vaccine recipients continued to be
followed for development of varicella. The estimated proportion of vaccine
recipients who remained varicella-free at the end of 7 years was 95%. The 23
cases of varicella that occurred in vaccine recipients over the 7-year
period were considerably milder than natural varicella. The average number
of lesions was 53, 50% of the children had non-vesicular rashes, and 14% of
the children had a temperature greater than or equal to 38.9 degrees C (102
degrees F), oral. The persistence of antibody in a subset of vaccine
recipients followed for 6 years was 100%.